ImmuCell Corporation
$8.02
▲
1.42%
2026-04-21 07:26:00
immucell.com
NCM: ICCC
Explore ImmuCell Corporation stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$72.74 M
Current Price
$8.02
52W High / Low
$8.23 / $4.52
Stock P/E
—
Book Value
$2.99
Dividend Yield
—
ROCE
4.28%
ROE
-3.81%
Face Value
—
EPS
$-0.12
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
73
Beta
0.31
Debt / Equity
48.77
Current Ratio
4.26
Quick Ratio
1.93
Forward P/E
-64.32
Price / Sales
2.32
Enterprise Value
$73.39 M
EV / EBITDA
14.17
EV / Revenue
2.65
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Filana Therapeutics, Inc. | $1.75 | — | $84.54 M | — | -128.99% | -82.66% | $2.27 / $1.53 | $1.54 |
| 2. | Grace Therapeutics, Inc. | $4.59 | — | $71.03 M | — | -23.81% | -10.22% | $5.18 / $2 | $4.19 |
| 3. | Dianthus Therapeutics, Inc. | $91.92 | — | $5 B | — | -35.57% | -38.38% | $96.5 / $16.64 | $11.41 |
| 4. | Insmed Incorporated | $143.43 | — | $31.02 B | — | -55.4% | -2.49% | $212.75 / $63.81 | $3.45 |
| 5. | Pasithea Therapeutics Corp. | $0.72 | — | $18.52 M | — | -37.74% | -58.36% | $3.79 / $0.28 | $2.39 |
| 6. | Solid Biosciences Inc. | $8.49 | — | $835.34 M | — | -90.02% | -1.1% | $8.87 / $2.41 | $2.28 |
| 7. | MBX Biosciences, Inc. | $33.78 | — | $1.6 B | — | -26.53% | -27.76% | $44.89 / $7.09 | $8.22 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 7.63 M | 5.51 M | 6.44 M | 8.07 M | 7.75 M | — |
| Operating Profit | -0.06 M | 0.02 M | 0.57 M | 1.12 M | 0.62 M | — |
| Net Profit | -2.85 M | -0.14 M | 0.5 M | 1.45 M | 0.51 M | — |
| EPS in Rs | -0.31 | -0.02 | 0.06 | 0.16 | 0.06 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 27.64 M | 26.49 M | 17.47 M | 18.57 M |
| Operating Profit | 1.65 M | -1.64 M | -5.75 M | -2.3 M |
| Net Profit | -1.04 M | -2.16 M | -5.77 M | -2.49 M |
| EPS in Rs | -0.11 | -0.24 | -0.64 | -0.28 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 42.53 M | 45.1 M | 43.81 M | 44.86 M |
| Total Liabilities | 15.48 M | 17.58 M | 18.82 M | 14.48 M |
| Equity | 27.06 M | 27.52 M | 24.99 M | 30.38 M |
| Current Assets | 16.94 M | 15.04 M | 11.47 M | 13.99 M |
| Current Liabilities | 3.98 M | 4.41 M | 4.2 M | 3.07 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 2.48 M | 0.36 M | -4.67 M | -1.54 M |
| Investing CF | -1.21 M | -0.46 M | -1.89 M | -3.96 M |
| Financing CF | -1.21 M | 2.88 M | 1.75 M | 1.11 M |
| Free CF | 1.22 M | -0.11 M | -6.57 M | -5.52 M |
| Capex | -1.25 M | -0.47 M | -1.89 M | -3.98 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 51.64% | -5.9% | — | — |
| Earnings Growth % | 62.65% | -131.56% | — | — |
| Profit Margin % | -8.14% | -33.05% | -13.43% | — |
| Operating Margin % | -6.19% | -32.9% | -12.38% | — |
| Gross Margin % | 29.97% | 22.15% | 41.19% | — |
| EBITDA Margin % | 4.03% | -14.88% | 1.88% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.